CRAIG W. CARLSON, MBA
CHIEF EXECUTIVE OFFICER

Over the past 25 years of his career, Craig has held senior financial and operational positions in the biotech, biopharmaceutical, and medical device industries. He has significant experience raising capital from private and public markets, directing M&A activities, and has also had significant international experience having been responsible for various subsidiaries in China, Korea and the United Kingdom. Craig holds an MBA from Stanford University.

Craig joined Stemedica in 2014 as Chief Financial Officer.  Previously, Craig was the Senior Vice President, Chief Financial Officer and Corporate Secretary at Talon Therapeutics, a specialty bio-pharmaceutical company that received accelerated approval for its lead product to treat ALL. He was responsible for all finance, accounting, SEC filings, investor relations, information technology, human resources, and intellectual property with financial oversight on clinical trials. During his time at Talon, he played an integral role in securing $100 million in financing; managed the Goldman Sachs M&A efforts; updated and streamlined Sarbanes Oxley controls and procedures; renegotiated licensing and royalty agreements, and actively participated in positioning the company for sale to Spectrum Pharmaceuticals in 2013.

He served as Senior Vice President, Chief Financial Officer, Chief Operating Officer and Managing Director UK for Cygnus Inc., a medical device company focused on manufacturing transdermal drug delivery systems and non-invasive glucose monitoring devices. At Cygnus, Craig led the fundraising efforts resulting in more than $250 million.  He led the licensing negotiations for U.S. sales and distribution agreements as well as the national launch of the world’s first non-invasive glucose monitoring device. He was instrumental in the company’s sale of their transdermal patch business division to Johnson & Johnson.

Craig was the Chief Financial Officer at Neurobiological Technologies, a biotech company focused on Phase III trials for Ischemic Stroke, where he was instrumental in raising over $70 million in the midst of a difficult funding environment. He also served as the Chief Financial Officer and Chief Operating Officer of a privately held new business incubator responsible for, among other things, managing subsidiaries in China and Korea.